IVF
INVO Fertility, Inc.1.1800
-0.0100-0.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
17.85MP/E (TTM)
-Basic EPS (TTM)
-294.88Dividend Yield
0%Recent Filings
8-K
INVO closes $760K clinic acquisition
INVO Fertility closed its $760,000 acquisition of Family Beginnings P.C. on February 18, 2026, paying $360,000 cash (net $210,000 after holdback) and 400 shares of Series D Preferred stock valued at $400,000. Buyer took non-medical assets while Fertility, P.A. bought clinical assets for $100; a 10-year MSA followed, with Buyer earning 20% of costs. Deal expands INVO's clinic network. Integration locked in.
8-K
INVO secures $7.5M warrant exercise
INVO Fertility inked an inducement deal on January 28, 2026, prompting an institutional investor to exercise existing warrants for 4,733,728 shares at $1.59 each, netting ~$7.5M gross proceeds. In exchange, INVO issued new unregistered warrants for 9,467,456 shares at $1.59, exercisable post-stockholder approval for Nasdaq compliance. Cash bolsters liquidity, but locks in no variable rate deals for months. New warrants hinge on shareholder nod.
8-K
Authorized shares soar 40x
INVO Fertility shareholders approved increasing authorized common shares from 6.25M to 250M on January 22, 2026, enabling future issuances. They also ratified the auditor, approved a warrant share issuance under Nasdaq rules, and boosted the 2019 Stock Incentive Plan to 1M shares. Capacity unlocked. Yet dilution risk looms for existing holders.
8-K
CFO swap boosts growth focus
INVO Fertility appointed Terah Krigsvold as CFO effective December 30, 2025, replacing Andrea Goren, who shifts to chief business officer and CEO of INVO Centers LLC. Both earn $250,000 base salaries with up to 50% bonuses. This realigns leadership to drive clinic acquisitions and growth. No disagreements prompted Goren's move.
8-K
INVO signs $750K clinic asset deal
INVO Fertility signed an asset purchase agreement on December 15, 2025, to acquire non-clinical assets of Family Beginnings' Indianapolis fertility clinic for $750,000—$350,000 cash (less $150,000 holdback) plus $400,000 in Series D preferred stock. Closing, expected by February 27, 2026, hinges on agreements including Dr. Donahue's three-year employment and five-year non-compete. Deal expands INVO's clinic network while retaining key physician. Risks include potential termination if conditions unmet.
IPO
Employees
Sector
Industry
AORT
Artivion, Inc.
45.91+0.54
CCEL
Cryo-Cell International, Inc.
3.80+0.06
COCH
Envoy Medical, Inc.
0.72-0.03
FEMY
Femasys Inc.
0.85-0.01
INMD
InMode Ltd.
14.48+0.15
NIVF
NewGenIvf Group Limited
0.91-0.03
NVCR
NovoCure Limited
12.93-0.04
NVNO
enVVeno Medical Corporation
0.32+0.01
VERO
Venus Concept Inc.
2.26+0.59
YBGJ
Yubo International Biotech Limi
0.01+0.00